Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
In the last 90 days, Atea Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 126 institutions reported holding it in 13F filings for Q3 2026, worth $307.4M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 19, 2026
- $315.6M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $168.1K in total
- 1
- 13F holdersQ3 2026, +3 vs. previous quarter
- 126
- 13F valueReported value at the end of Q3 2026
- $307.4M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$158.3M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.01M
- Shares sold short
- Change
- −62.2K
- −2.0% vs. previous
- Days to cover
- 9.55
- At average daily volume
Superinvestors holding AVIR, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding AVIR at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Atea Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2026 (view filing)8:59 PM ET | Nov 16-18 | 2 days | Polsky BruceDirector | SSale | −41.2K | $4.08 | −$168.1K | −20.6%158.6K after | 3 lots |
| May 21, 2026 (view filing) | May 18 | 3 days | Murphy Polly A.Director | PPurchase | +6.10K | $4.17 | +$25.4K | +7.1%92.1K after | Amended |
| Jan 17, 2025 (view filing) | Jan 15-16 | 2 days | Berger Franklin MDirector | PPurchase | +25.0K | $3.26 | +$81.5K | +5.5%476.9K after | Amended2 lots |
| Dec 12, 2024 (view filing) | Dec 10 | 2 days | Berger Franklin MDirector | SSale | −359.6K | $2.85 | −$1.02M | −44.3%451.9K after | |
| Sep 19, 2024 (view filing) | Sep 17-19 | 2 days | Sommadossi Jean-PierrePresident, CEO, and Chairman | SSale | −58.0K | $4.04 | −$234.2K | −1.0%5.87M after | 3 lots10b5-1 |
| Jun 21, 2024 (view filing) | Jun 20 | 1 day | Polsky BruceDirector | SSale | −17.5K | $3.49 | −$61.2K | −21.1%65.6K after | |
| Jun 7, 2024 (view filing) | Jun 5 | 2 days | Sommadossi Jean-PierrePresident, CEO, and Chairman | SSale | −1.01K | $4.00 | −$4.02K | 0.0%5.92M after | 10b5-1 |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Corcoran AndreaSee Remarks | SSale | −15.8K | $3.84 | −$60.8K | −2.3%670.2K after | |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Sommadossi Jean-PierrePresident, CEO, and Chairman | SSale | −56.9K | $3.85 | −$219.1K | −32.8%116.6K after | 10b5-1 |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Horga Maria ArantxaChief Medical Officer | SSale | −15.9K | $3.84 | −$60.9K | −38.2%25.7K after |
Top 10 13F holders, Q3 2026
See all 126 holdersThe largest institutional positions in Atea Pharmaceuticals, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 12,030,704 | $62.7M | 0.00% | +26,640+0.2% | Added |
| BlackRock, Inc. | 9,061,530 | $47.2M | 0.00% | +341,453+3.9% | Added |
| BML Capital Management, LLC | 6,753,658 | $35.2M | 18.88% | −198,672−2.9% | Reduced |
| Tang Capital Management LLC | 4,814,700 | $25.1M | 1.15% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,906,793 | $15.1M | 0.00% | −58,069−2.0% | Reduced |
| Acadian Asset Management LLC | 2,338,271 | $12.2M | 0.01% | +303,079+14.9% | Added |
| Bain Capital Life Sciences Investors, LLC | 2,075,639 | $10.8M | 0.73% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 1,910,289 | $9.96M | 0.00% | −48,146−2.5% | Reduced |
| State Street Corp | 1,626,938 | $8.48M | 0.00% | −25,461−1.5% | Reduced |
| Two Sigma Investments, LP | 1,303,341 | $6.79M | 0.00% | −203,356−13.5% | Reduced |
Holders of 5% or more of AVIR
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Atea Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%12.0M shares | +3.40 ppfrom 11.60% | Feb 8, 202110 filings | May 6, 2026 | SEC |
| Sommadossi Jean-Pierre | 13G/A | 11.00%9.08M shares | +0.90 ppfrom 10.10% | Feb 10, 20216 filings | Nov 13, 2026 | SEC |
| BML Investment Partners, L.P. | 13G | 9.90%7.81M shares | +1.40 ppfrom 8.50% | Oct 2, 20235 filings | Feb 9, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.10%6.08M shares | – | Apr 23, 20251 filing | Apr 23, 2025 | SEC |
| Tang Capital Management LLC | 13G | 6.00%4.81M shares | New | Oct 6, 20261 filing | Oct 6, 2026 | SEC |